Maintenance Therapy With ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients Who Have Previously Received ONT-10 [EXTENSION OF 700197097]
Phase of Trial: Phase I
Latest Information Update: 24 Jun 2016
At a glance
- Drugs ONT 10 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Oncothyreon
- 01 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Nov 2013 New trial record